Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Hood Acquires 3,000 Restricted Shares at $13.64 in Winchester Bancorp Grant

Director William Preston Hood filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of restricted stock and stock options in Winchester Bancorp, Inc./MD/ (NASDAQ:WSBK) on November 4, 2026.

Aditi Sarkar | 06 November 2026

Anne Arvia Plans to Sell 943 GATX Shares via Rule 144

Director Anne Arvia of GATX Corp filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 943 shares of GATX common stock under Rule 144 of the Securities Act of 1933.

Aditi Sarkar | 06 November 2026

CTT Pharmaceutical CEO Khouri Buys 9,000 Shares at $0.05

CTT Pharmaceutical Holdings, Inc. filed a Statement of Changes in Beneficial Ownership on November 6, 2026, disclosing a purchase of 9,000 shares of CTTH common stock by the company's CEO and Director, Ryan Khouri, on November 4, 2026.

Shwetambri Chauhan | 06 November 2026

Citi Launches BSX-Linked Autocallable Notes Due Jan 2028

Citigroup Global Markets Holdings Inc. filed a free writing prospectus on November 6, 2026, disclosing preliminary terms for Autocallable Contingent Coupon Equity Linked Securities linked to Boston Scientific Corporation (BSX) with a stated principal amount of $1,000 per security and a maturity date of …

Nitish Kishor | 06 November 2026

Hood Acquires 3,000 Restricted Shares and 7,500 Options at Winchester Bancorp

Director David Preston Hood filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of restricted stock and stock options in Winchester Bancorp, Inc./MD/ (NASDAQ:WSBK) on November 4, 2026.

Vinay Lochav | 06 November 2026

T. Rowe Price Reports 13.1% Stake in Cabaletta Bio

T. Rowe Price Investment Management, Inc. filed Amendment No. 6 to its Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 28,138,417 shares of Cabaletta Bio Inc. common stock as of October 31, 2026.

Aditi Sarkar | 06 November 2026

T. Rowe Price Reports 10.8% Stake in Pacific Biosciences

T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 33,445,993 shares of Pacific Biosciences of California common stock as of October 31, 2026.

Anjali Anand | 06 November 2026

Southside Bancshares CAO Pinkley Exercises Options, Sells Shares Nov 5

April Pinkley, Chief Accounting Officer of Southside Bancshares Inc, filed a Form 4 on November 6, 2026, disclosing option exercises and open-market sales of common stock transacted on November 5, 2026.

Vinay Lochav | 06 November 2026

T. Rowe Price Reports 10.3% Stake in Xenon Pharmaceuticals

T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 9,996,124 shares of Xenon Pharmaceuticals Inc. common stock as of October 31, 2026.

Aditi Sarkar | 06 November 2026

T. Rowe Price Reports 10.2% Stake in WaterBridge Class A

T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G on November 6, 2026, disclosing beneficial ownership of 5,663,206 shares of WaterBridge Infrastructure Class A common stock as of October 31, 2026.

Anjali Anand | 06 November 2026
Support

Hi! How can we help you today?

Loading…